Sanofi Pasteur Vaxdesign Corp — Federal Contractor Profile
SANOFI PASTEUR VAXDESIGN CORP: $85.1M in Vaccine Development Contracts
Contractor Overview
Total Contract Value: $85,091,895 ($85.1M)
Total Awards: 4
Company Profile
SANOFI PASTEUR VAXDESIGN CORP is a federal contractor with a total government contract value of $85.1 million, spanning four contracts with an average size of $21,272,974. The company specializes in vaccine development and production, which is a critical component of public health initiatives. However, the contractor has not secured any recent contracts, indicating a potential slowdown in new business. The lack of recent contracts and the absence of specific agency clients suggest a need for further investigation into the company's current business strategy and performance. The contractor's sole-source rate is not applicable, as there are no sole-source contracts, and the competitive win rate is 100%, indicating a strong competitive position in the market. The company's contract patterns reveal a focus on vaccine development and production, which is a key area of government interest. However, the lack of recent contracts and the absence of specific agency clients raise concerns about the company's current business health and dependency risks.
Specializations
- Vaccine Development
- Vaccine Production
- Public Health Initiatives
- Biological Product Manufacturing
- Clinical Trials
Contractor Metrics
Average Contract Size: $0
Competitive Win Rate: 100%
Agency Concentration: N/A
Growth Trajectory: Stable
Sole Source Rate: 0%
Recompete Rate: N/A
Competitive Position
SANOFI PASTEUR VAXDESIGN CORP holds a strong competitive position in the vaccine development and production market. The company's 100% competitive win rate and the absence of sole-source contracts indicate a robust presence in the market. However, the lack of recent contracts and the absence of specific agency clients suggest that the company may be facing challenges in securing new business, which could impact its long-term stability.
Value to Taxpayers
SANOFI PASTEUR VAXDESIGN CORP provides critical services in vaccine development and production, which are essential for public health initiatives. The company's strong competitive position and 100% competitive win rate suggest that it is delivering value to taxpayers. However, the lack of recent contracts and the absence of specific agency clients raise concerns about the company's current business health and the potential for cost escalation or performance issues.
Agency Relationships
The contractor's lack of specific agency clients and recent contracts suggests a need for further investigation into its current business relationships. The absence of specific agency clients raises concerns about dependency risks and concentration concerns. The company's strong competitive position and 100% competitive win rate suggest that it is well-positioned to secure contracts with various agencies, but the lack of recent contracts and specific agency clients indicates a potential need for strategic realignment.
Red Flags
- Lack of recent contracts: The absence of recent contracts may indicate challenges in securing new business, which could impact the company's long-term stability.
- No specific agency clients: The lack of specific agency clients raises concerns about dependency risks and concentration concerns.
- No sole-source contracts: The absence of sole-source contracts suggests that the company is not relying on non-competitive contracts, but it also indicates a need for further investigation into the nature of its contracts.
Green Flags
- 100% competitive win rate: The company's strong competitive position and 100% competitive win rate suggest that it is delivering value to taxpayers.
- Strong specialization: The company's focus on vaccine development and production is a critical area of government interest, indicating a strong specialization in a key sector.
- No sole-source contracts: The absence of sole-source contracts suggests that the company is not relying on non-competitive contracts, which is a positive indicator.
Key Contracts
SANOFI PASTEUR VAXDESIGN CORP has secured four contracts with a total value of $85.1 million, all of which are focused on vaccine development and production. The company's contracts are primarily competitive, with a 100% competitive win rate. The contracts reveal the company's core capabilities in vaccine development and production, which are critical for public health initiatives. The lack of recent contracts and the absence of specific agency clients suggest a need for further investigation into the company's current business strategy and performance. The company's strong competitive position and 100% competitive win rate suggest that it is delivering value to taxpayers, but the lack of recent contracts and specific agency clients raises concerns about the company's current business health and the potential for cost escalation or performance issues.
Frequently Asked Questions
What does SANOFI PASTEUR VAXDESIGN CORP do for the federal government?
SANOFI PASTEUR VAXDESIGN CORP specializes in vaccine development and production, which is a critical component of public health initiatives. The company's services include the development, production, and distribution of vaccines, as well as clinical trials and public health initiatives.
How much taxpayer money does SANOFI PASTEUR VAXDESIGN CORP receive?
SANOFI PASTEUR VAXDESIGN CORP has secured four contracts with a total value of $85.1 million. The average contract size is $21,272,974, indicating a significant investment in vaccine development and production for the federal government.
Is SANOFI PASTEUR VAXDESIGN CORP good value for taxpayer money?
SANOFI PASTEUR VAXDESIGN CORP provides critical services in vaccine development and production, which are essential for public health initiatives. The company's strong competitive position and 100% competitive win rate suggest that it is delivering value to taxpayers. However, the lack of recent contracts and the absence of specific agency clients raise concerns about the company's current business health and the potential for cost escalation or performance issues.
How does SANOFI PASTEUR VAXDESIGN CORP win its contracts?
SANOFI PASTEUR VAXDESIGN CORP has a 100% competitive win rate, indicating that it is winning contracts through competitive bidding. The company's strong specialization in vaccine development and production, as well as its robust presence in the market, contribute to its competitive position.
What agencies use SANOFI PASTEUR VAXDESIGN CORP most?
The contractor's lack of specific agency clients and recent contracts suggests a need for further investigation into its current business relationships. The absence of specific agency clients raises concerns about dependency risks and concentration concerns. The company's strong competitive position and 100% competitive win rate suggest that it is well-positioned to secure contracts with various agencies, but the lack of recent contracts and specific agency clients indicates a potential need for strategic realignment.
What are the risks of relying on SANOFI PASTEUR VAXDESIGN CORP?
The lack of recent contracts and the absence of specific agency clients raise concerns about the company's current business health and the potential for cost escalation or performance issues. The company's strong competitive position and 100% competitive win rate suggest that it is delivering value to taxpayers, but the lack of recent contracts and specific agency clients raises concerns about dependency risks and concentration concerns.
How does SANOFI PASTEUR VAXDESIGN CORP compare to similar contractors?
SANOFI PASTEUR VAXDESIGN CORP holds a strong competitive position in the vaccine development and production market. The company's 100% competitive win rate and the absence of sole-source contracts indicate a robust presence in the market. However, the lack of recent contracts and the absence of specific agency clients suggest that the company may be facing challenges in securing new business, which could impact its long-term stability. The company's strong specialization in vaccine development and production, as well as its robust presence in the market, contribute to its competitive position, but the lack of recent contracts and specific agency clients indicates a potential need for strategic realignment.
Recent Federal Contracts
Sanofi Pasteur Vaxdesign Corp has 2 federal contracts on record. Below are the largest awards:
| Contract | Agency | Amount | Type |
|---|---|---|---|
| DOI Spends $25.6M on Accelerated Vaccine Creation and Testing with Sanofi Pas... | Department of the Interior | $25.6M | N/A |
| HHS Awards $16.9M for Clinical Trial Development, Primarily to Large Firms | Department of Health and Human Services | $16.9M | N/A |